Clinical and Immunologic Correlates of Vasodilatory Shock Among Ebola Virus-Infected Nonhuman Primates in a Critical Care Model.


Journal

The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675

Informations de publication

Date de publication:
13 Nov 2023
Historique:
medline: 17 11 2023
pubmed: 1 9 2023
entrez: 31 8 2023
Statut: ppublish

Résumé

Existing models of Ebola virus infection have not fully characterized the pathophysiology of shock in connection with daily virologic, clinical, and immunologic parameters. We implemented a nonhuman primate critical care model to investigate these associations. Two rhesus macaques received a target dose of 1000 plaque-forming units of Ebola virus intramuscularly with supportive care initiated on day 3. High-dimensional spectral cytometry was used to phenotype neutrophils and peripheral blood mononuclear cells daily. We observed progressive vasodilatory shock with preserved cardiac function following viremia onset on day 5. Multiorgan dysfunction began on day 6 coincident with the nadir of circulating neutrophils. Consumptive coagulopathy and anemia occurred on days 7 to 8 along with irreversible shock, followed by death. The monocyte repertoire began shifting on day 4 with a decline in classical and expansion of double-negative monocytes. A selective loss of CXCR3-positive B and T cells, expansion of naive B cells, and activation of natural killer cells followed viremia onset. Our model allows for high-fidelity characterization of the pathophysiology of acute Ebola virus infection with host innate and adaptive immune responses, which may advance host-targeted therapy design and evaluation for use after the onset of multiorgan failure.

Sections du résumé

BACKGROUND BACKGROUND
Existing models of Ebola virus infection have not fully characterized the pathophysiology of shock in connection with daily virologic, clinical, and immunologic parameters. We implemented a nonhuman primate critical care model to investigate these associations.
METHODS METHODS
Two rhesus macaques received a target dose of 1000 plaque-forming units of Ebola virus intramuscularly with supportive care initiated on day 3. High-dimensional spectral cytometry was used to phenotype neutrophils and peripheral blood mononuclear cells daily.
RESULTS RESULTS
We observed progressive vasodilatory shock with preserved cardiac function following viremia onset on day 5. Multiorgan dysfunction began on day 6 coincident with the nadir of circulating neutrophils. Consumptive coagulopathy and anemia occurred on days 7 to 8 along with irreversible shock, followed by death. The monocyte repertoire began shifting on day 4 with a decline in classical and expansion of double-negative monocytes. A selective loss of CXCR3-positive B and T cells, expansion of naive B cells, and activation of natural killer cells followed viremia onset.
CONCLUSIONS CONCLUSIONS
Our model allows for high-fidelity characterization of the pathophysiology of acute Ebola virus infection with host innate and adaptive immune responses, which may advance host-targeted therapy design and evaluation for use after the onset of multiorgan failure.

Identifiants

pubmed: 37652048
pii: 7257483
doi: 10.1093/infdis/jiad374
pmc: PMC10651209
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

S635-S647

Subventions

Organisme : HHS
Pays : United States

Informations de copyright

Published by Oxford University Press on behalf of Infectious Diseases Society of America 2023.

Déclaration de conflit d'intérêts

Potential conflicts of interest. All authors: No reported conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Références

J Infect Dis. 2021 Aug 16;224(4):632-642
pubmed: 33367826
Intensive Care Med Exp. 2019 Sep 13;7(1):54
pubmed: 31520194
iScience. 2023 Jan 07;26(2):105948
pubmed: 36756375
Clin Exp Immunol. 2021 Aug;205(2):119-127
pubmed: 33969476
J Exp Med. 2001 Nov 5;194(9):1361-73
pubmed: 11696600
Viruses. 2020 Jul 14;12(7):
pubmed: 32674252
J Infect Dis. 2011 Nov;204 Suppl 3:S1000-10
pubmed: 21987736
Emerg Infect Dis. 2002 May;8(5):503-7
pubmed: 11996686
Cell. 2020 Nov 25;183(5):1383-1401.e19
pubmed: 33159858
Lab Invest. 2000 Feb;80(2):171-86
pubmed: 10701687
JCI Insight. 2020 May 21;5(10):
pubmed: 32434986
Sci Rep. 2017 Apr 26;7(1):1204
pubmed: 28446775
Nat Rev Immunol. 2011 Oct 10;11(11):762-74
pubmed: 21984070
Nature. 2000 Nov 30;408(6812):605-9
pubmed: 11117750
Am J Pathol. 2022 Jan;192(1):121-129
pubmed: 34626576
Blood. 2005 May 15;105(10):3965-71
pubmed: 15687242
Emerg Infect Dis. 2019 Feb;25(2):290-298
pubmed: 30666927
J Infect Dis. 2015 Oct 1;212 Suppl 2:S91-7
pubmed: 26063223
Nat Rev Immunol. 2008 Dec;8(12):958-69
pubmed: 19029990
J Leukoc Biol. 2019 Jan;105(1):113-121
pubmed: 30395351
Front Immunol. 2018 Jul 10;9:1593
pubmed: 30042766
J Leukoc Biol. 2000 Jan;67(1):97-103
pubmed: 10648003
Nat Med. 1999 Apr;5(4):423-6
pubmed: 10202932
Exp Cell Res. 2011 Mar 10;317(5):620-31
pubmed: 21376175
N Engl J Med. 2019 Dec 12;381(24):2293-2303
pubmed: 31774950
Immunology. 2022 Apr;165(4):371-385
pubmed: 34939192
Nature. 2003 Aug 7;424(6949):681-4
pubmed: 12904795
Annu Rev Pathol. 2017 Jan 24;12:387-418
pubmed: 27959626
J Clin Invest. 1999 Jul;104(1):115-21
pubmed: 10393705
N Engl J Med. 2016 Feb 18;374(7):636-46
pubmed: 26886522
Intensive Care Med. 2018 Aug;44(8):1266-1275
pubmed: 30062576
Cytometry A. 2015 Jul;87(7):636-45
pubmed: 25573116
Eur J Immunol. 2013 Nov;43(11):2797-809
pubmed: 24258910
J Infect Dis. 2018 Nov 22;218(suppl_5):S612-S626
pubmed: 29860496
Cell Rep. 2018 May 8;23(6):1806-1816
pubmed: 29742435
J Infect Dis. 2020 Oct 13;222(10):1745-1755
pubmed: 32498080
Nat Rev Immunol. 2013 Sep;13(9):621-34
pubmed: 23928573
Biochem Pharmacol. 2011 Aug 15;82(4):333-40
pubmed: 21640713
Immunity. 2020 Jul 14;53(1):217-232.e5
pubmed: 32668225
J Virol. 2007 Feb;81(3):1241-50
pubmed: 17108043
Science. 2016 Mar 18;351(6279):1339-42
pubmed: 26917593
Emerg Infect Dis. 2015 Oct;21(10):1777-83
pubmed: 26402165
J Infect Dis. 2016 Oct 15;214(suppl 3):S281-S289
pubmed: 27651412

Auteurs

Sydney R Stein (SR)

Laboratory of Virology, National Institute of Allergy and Infectious Diseases.
Emerging Pathogens Section, Critical Care Medicine Department, Clinical Center.
Critical Care Medicine Branch, National Heart, Lung, and Blood Institute.

Andrew P Platt (AP)

Laboratory of Virology, National Institute of Allergy and Infectious Diseases.
Emerging Pathogens Section, Critical Care Medicine Department, Clinical Center.
Critical Care Medicine Branch, National Heart, Lung, and Blood Institute.

Heather L Teague (HL)

Critical Care Medicine Branch, National Heart, Lung, and Blood Institute.
Pathogenesis and Therapeutics Section, Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda.

Scott M Anthony (SM)

Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick.

Rebecca J Reeder (RJ)

Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick.

Kurt Cooper (K)

Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick.

Russell Byrum (R)

Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick.

David J Drawbaugh (DJ)

Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick.

David X Liu (DX)

Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick.

Tracey L Burdette (TL)

Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick.

Kyra Hadley (K)

Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick.

Bobbi Barr (B)

Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick.

Seth Warner (S)

Laboratory of Virology, National Institute of Allergy and Infectious Diseases.
Emerging Pathogens Section, Critical Care Medicine Department, Clinical Center.
Critical Care Medicine Branch, National Heart, Lung, and Blood Institute.
Pathogenesis and Therapeutics Section, Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda.

Francisco Rodriguez-Hernandez (F)

Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick.

Cristal Johnson (C)

Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick.

Phil Stanek (P)

Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick.

Joseph Hischak (J)

Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick.

Heather Kendall (H)

Experimental Primate Virology Section, Comparative Medicine Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Poolesville, Maryland, USA.

Louis M Huzella (LM)

Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick.

Jeffrey R Strich (JR)

Critical Care Medicine Branch, National Heart, Lung, and Blood Institute.
Pathogenesis and Therapeutics Section, Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda.

Richard Herbert (R)

Experimental Primate Virology Section, Comparative Medicine Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Poolesville, Maryland, USA.

Marisa St Claire (M)

Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick.

Kevin M Vannella (KM)

Laboratory of Virology, National Institute of Allergy and Infectious Diseases.
Emerging Pathogens Section, Critical Care Medicine Department, Clinical Center.
Critical Care Medicine Branch, National Heart, Lung, and Blood Institute.

Michael R Holbrook (MR)

Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick.

Daniel S Chertow (DS)

Laboratory of Virology, National Institute of Allergy and Infectious Diseases.
Emerging Pathogens Section, Critical Care Medicine Department, Clinical Center.
Critical Care Medicine Branch, National Heart, Lung, and Blood Institute.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH